The toxin strychnine, the primary component of the traditional Chinese medicine, may act in the STAT3 pathway, investigators ...

A dry cough can be classified as acute or chronic, based on its duration ... through your mouth to see inside your airways).

for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC), today announced that it has completed enrollment in its Phase 2a trial for the ...

The company is advancing multiple trials, including a human abuse potential trial, a Phase IIb study for chronic cough in idiopathic pulmonary fibrosis (IPF), and a Phase IIa trial for refractory ...

Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy ...

Insilico Medicine plans to push its computer-designed drug into pivotal clinical trials after a phase 2a study demonstrated ...

Oren Livnat, an analyst from H.C. Wainwright, reiterated the Buy rating on Trevi Therapeutics (TRVI – Research Report). The associated ...

With its lead product candidate, Haduvio, the company aims to treat chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC). The Phase 2b CORAL trial for the ...

Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in idiopathic ...